| Previous Close | 62.36 |
| Open | 62.31 |
| Bid | 61.80 x 500 |
| Ask | 62.21 x 2800 |
| Day's Range | 61.72 - 62.34 |
| 52 Week Range | 57.18 - 66.80 |
| Volume | 9,366,722 |
| Avg. Volume | 8,751,817 |
| Market Cap | 169.03B |
| Beta | 0.97 |
| PE Ratio (TTM) | 39.39 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.88 (3.00%) |
| Ex-Dividend Date | 2017-06-13 |
| 1y Target Est | N/A |
- Zacks•10 hours ago
Key Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline
Why were Lilly's (LLY) shares down despite the company delivering a "beat and raise" quarter?
- 24/7 Wall St.•11 hours ago
Major Pharma Short Interest Takes a Big Step Back
The July 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
- Forbes•17 hours ago
The Startling History Behind Merck's New Cancer Blockbuster
The success of Merck’s blockbuster cancer drug pembrolizumab (Keytruda) was anything but inevitable. It was discovered accidentally, weathered two company acquisitions, and nearly out-licensed for next to nothing -- before it was developed in one of the most aggressive pharma programs in history.
